Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Flora Growth Corp. (NASDAQ: FLGC) Achieves Key Milestone in Global Expansion Plan with JustCBD Launch on Amazon UK

  • Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022
  • The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategy
  • JustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only program
  • Flora Growth is optimistic that this launch will allow the company to reach a larger consumer base as it works towards further expanding its operations across Europe

On February 28, 2022, Flora Growth (NASDAQ: FLGC) completed the acquisition of 100% equity interests of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand. The transaction, which involved a consideration of $16 million in cash and 9.5 million in privately issued Flora common shares, was a move by Flora Growth to explore global expansion opportunities and increase the company’s customer database (https://cnw.fm/ccydT).

By mid-May 2022, Flora Growth had already announced the expansion of its operational footprint in Europe and the United Kingdom to further its international growth strategy. But, more importantly, the move signaled the company’s assertive push to broaden the reach for its JustCBD’s 79 products registered with the UK Novel Foods, paving the way for meaningful distribution of its growing house of brands.

“Establishing our roots in the UK and EU will not only afford us opportunities to increase our distribution and grow market share, but it will generate actionable market insights for our team to continue to innovate and deliver the most

compelling experiences we can,” noted Luis Merchan, Flora Growth’s President and Chief Executive Officer (“CEO”) (https://cnw.fm/Nx2Jm).

In what marks a noteworthy milestone for Flora Growth and its expansion plan, the company announced that JustCBD would launch its Novel Foods registered CBD products on Amazon.co.uk.

JustCBD’s product line will be available on the site starting this month, making available a portfolio of the company’s best-selling gummies and tinctures.

“With health and wellness playing an increasingly important role in customers’ lives, we are excited to increase the selection of quality CBD products offered to Amazon customers in the UK,” noted Hussein Rakine, the CEO of JustCBD.

“The JustCBD team looks forward to working closely with Amazon to expand our product offering to other countries as our partnership and brand presence in the United Kingdom Grows,” he added (https://cnw.fm/i76q9).

The CBD market in the UK is currently valued at £700 million and is projected to hit £1 billion by 2025. This growth is attributed mainly to the UK’s regulatory framework, which is regarded as the most evolved in the world. Such structures have seen key corporations such as Amazon venturing into this market, introducing a pilot-only program that includes vendors who have already demonstrated compliance with the UK CBD Novel Food regulations.

JustCBD has already undergone the Novel Food regulations approval process and has been awarded the necessary authorization proving that its products are safe for consumption and labeled correctly. With the launch of its product line on Amazon UK, Flora Growth is optimistic that it will reach a larger consumer base even as it works towards further expanding its operations across Europe.

“International growth is a key objective of our company’s strategy,” noted Mr. Merchan.

“The launch of Amazon UK allows Flora to reach a larger consumer base in search of quality CBD products. We are excited to continue expanding our operations in Europe and to deliver top-quality cannabis-related products to customers aiming to improve their health and wellness,” he added.

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC 

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New Details Emerge on Possible Congressional Omnibus Bill on Marijuana Policy Reform

Two members of Congress have revealed that high-level legislators are discussing putting together a package of cannabis proposals that could be enacted in a marijuana omnibus law this year. Furthermore, sources have revealed that these discussions cover a wide range of issues, not just the expungement and cannabis banking reforms that have been the crux of cannabis discussion in recent times.

The two Congressmen revealed that the discussions involve incremental reform and comprehensive cannabis legalization. Those in the know say that these discussions have the potential to result in actionable, bipartisan cannabis policy, a feat that has eluded Congress for decades.

Sources say legislators have discussed adding standalone language from cannabis bills that deal with issues such as research expansion, lack of veteran access to medical cannabis, drug-sentencing reform and granting the cannabis industry access to Small Business Administration (SBA) loan programs.

Senate Majority Leader Chuck Schumer, an outspoken supporter of cannabis reform, has been working on a broad cannabis legalization bill with his colleagues for the past couple of months and has regularly asked for input on the Cannabis Administration and Opportunity Act (CAOA). He is sponsoring the comprehensive legalization bill with Senate Finance Committee Chair Ron Wyden and Senator Cory Booker and is expected to officially file it this month after several delays.

News of the bipartisan cannabis package was first revealed by Representatives Dave Joyce and Ed Perlmutter during an International Cannabis Bar Conference. Perlmutter stated that his Secure and Fair Enforcement (SAFE) Banking Act would also be a part of the package.

He noted that members of Congress have been also interested in Joyce’s Harnessing Opportunities by Pursuing Expungement (HOPE) Act, which would provide local and state incentives to encourage the expungement of prior cannabis-related offenses, and proposals to expand cannabis research and grant war veterans access to medical marijuana.

Sources involved in the negotiations say that expungements, banking, veterans and research are just part of what is being discussed. However, they said that negotiations are still tentative and legislators haven’t yet reached a consensus.

One hot topic that is sure to be discussed is the industry’s lack of access to SBA loans and entrepreneurial programs. Even though cannabis businesses pay billions of dollars in taxes, federal law prohibits them from accessing any SBA programs.

Senator Jacky Rosen recently sent a letter to the head of the Small Business Administration urging the agency to expand access to businesses in the state-legal cannabis sector.

It remains to be seen whether this new flurry of activity will result in any meaningful policy changes that ease the operations of companies such as Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Congressional Researchers Find Legalization of Marijuana Is Affecting Mexican Cartel Profits

Procannabis policies across America are achieving one key objective of legalization: drawing consumers away from the illicit market and reducing illegal sales. According to a report from Congressional researchers, cannabis legalization in America and Canada has dampened the demand for illegal cannabis from Mexico.

The report from the Congressional Research Service (CRS) is an updated version of one released in 2020 and contains fairly consistent language with the 2020 version. Like the 2020 report, it shows how cannabis reform and legalization have affected the international drug trade.

Analysis from the CRS showed that U.S. seizures of smuggled cannabis started to drop back in 2019. Furthermore, the report stated that authorities predict American demand for Mexican marijuana will continue decreasing, partly due to demand for other illicit synthetic drugs.

The Congressional Research Service wrote in both the 2020 and the recent version that the legalization of medical and recreational cannabis in dozens of U.S. states and Canada had reduced the drug’s value to trafficking organizations. The 2022 version adds that steps taken by Mexican authorities to legalize cannabis have further reduced its value as an illicit commodity. In June 2021, Mexican lawmakers passed a bill to legalize adult-use cannabis in the country.

However, the report noted that drug violence in Mexico still persists even as drug cartels ditch plant-based drugs such as opium and cannabis and move to synthetic drugs. Several agencies and institutions have confirmed that pro-cannabis policies are stifling drug cartels from Mexico.

For example, in its fiscal year 2023 performance budget summary, the Drug Enforcement Administration (DEA) acknowledged that increasing domestic marijuana production dampened cannabis smuggling from Mexico. The DEA specifically stated that domestic-produced cannabis had largely supplanted Mexican cannabis even though Mexico remained a major foreign marijuana supplier. The agency also discussed shifting trends in marijuana production and in-house efforts to boost long-neglected marijuana research.

A 2018 study by the Cato Institute concluded that America’s growing state-legal cannabis industry had significantly undercut marijuana smuggling. Border Patrol seizure data showed that smuggling had dropped by an estimated 70% in five years. Data from the Federal Bureau of Investigations (FBI) shows that the number of local cannabis-related arrests has also been on a decline for the first time in four years.

There are fewer marijuana-related prosecutions as well, with a recent U.S. Sentencing Commission (USCC) report revealing that less than 1,000 people were charged with cannabis trafficking offenses in 2021, and in 2020, the cases numbered 1,118.

It is interesting to observe that today, legally produced cannabis products from entities such as American Cannabis Partners are proving to be a big help in reducing the work of various law enforcement agencies charged with preventing marijuana from Mexico from getting onto U.S. streets. This is an intriguing development given the negative attitude that law enforcement regards marijuana, whether locally sourced or imported.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces $5M Share Repurchase Program

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors has authorized the repurchase of up to $5 million of its outstanding common shares as market conditions and the company’s liquidity warrant. “We believe that the potential to repurchase our shares at these levels represents a compelling opportunity to deploy available cash to drive shareholder value,” said Luis Merchan, Flora’s chairman and CEO. “Flora continues to move assertively to execute its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses. We are confident in the company’s short, medium and long-term growth prospects based on our strong in-market brand portfolio together with our cultivation and export capabilities and life sciences research. The repurchase program affords us the opportunity to increase our ownership in our portfolio of high-quality brands through our shares, which in our view are trading well below NAV.”

To view the full press release, visit https://cnw.fm/2zFZw

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — White House FAQ Reveals That Prospective Interns Will Be Asked About Past Cannabis Use

Earlier this week, the Biden Administration announced that individuals who would like to intern at the White House would be required to disclose any previous drug use. This is despite repeated requests to stop penalizing employees who admit to past use of cannabis.

A new White House Internship program FAQ states that applicants going through the hiring process will be required to fill out a security clearance form. The data collected by this form may affect the eligibility of the candidates, especially if it includes information on past consumption of marijuana, even if it was legal under state law.

In the early days of this administration, the Biden White House was criticized over reports that staffers were being penalized or terminated on the basis of past cannabis use. President Biden has been against marijuana’s legalization for some time now, with a former White House press secretary reiterating that the president hadn’t changed his stance on maintaining federal prohibition soon after Senate Majority Leader Chuck Schumer and his colleagues introduced a draft bill to legalize cannabis in 2021.

However, while campaigning in 2020, Biden ran on a pledge to enact reforms such as the expungement of previous records, the decriminalization of marijuana possession and respecting the rights of states to enact their own laws.

Since the president assumed office, the administration has made no strides to enact any of these changes, instead choosing to fire its staffers over cannabis and extending a provision that prevented D.C. from legalizing the sale of marijuana.

Results from a poll released earlier in January show that more than one-half of Americans feel that the president has made little progress on his pledge to decriminalize cannabis in his first year in office, with most individuals expecting that little will be done to advance reform as his term continues. The president has received numerous letters from advocates, legislators, celebrities and individuals affected by criminalization, calling on him to do something about the individuals who are still behind bars over marijuana.

While Biden has granted clemency to some individuals with nonviolent federal drug convictions on their records, not much else has been done. This is despite findings from a report by the Congressional Research Service showing that Biden has the power to grant mass pardons for marijuana offenses.

For her part, Vice President Kamala Harris stated in 2021 that the administration wasn’t focused on making progress on its cannabis reform pledges because it was overburdened with other issues.

It is this inaction at the highest level of government that is holding back the marijuana industry and entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) from growing their footprint across the country as quickly as they would desire.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — The Do’s and Don’ts as Thailand Eases Marijuana Restrictions

Thailand has become the first country in Asia to decriminalize the cultivation and sale of marijuana. However, Thai residents won’t be living in a recreational cannabis paradise anytime soon.

The Asian country plans on enacting strict cannabis policies and tough penalties for anyone caught indulging in recreational weed. According to Thai Health Minister Anutin Charnvirakul, the move is meant to boost Thailand’s economy by tapping into the billion-dollar medical cannabis industry.

Anutin cautions against using cannabis recreationally as the country still has laws that control the consumption of marijuana products in a “nonproductive” way. Rather than launch a recreational market, Thailand’s new cannabis laws will allow citizens to grow and sell cannabis and hemp products.

Restaurants will also be allowed to stock and serve cannabis-infused drinks and foods as long as the product contain less than 0.2% of delta-9 tetrahydrocannabinol (THC). This is the main component in marijuana that makes users feel “high.” Hemp, which is virtually identical to cannabis except for its THC levels, has minimal to no THC.

Thailand’s cannabis policies will mainly be centered on medical marijuana. Already allowed by dozens of territories around the world, medical marijuana has been found to have potential in treating a variety of medical conditions.

Anutin says the country has no plans to be a recreational cannabis haven for tourists either, stating that Thailand will only promote medical cannabis policies. Tourists who wish to purchase medical cannabis products are free to visit, but those coming to indulge in adult-use cannabis are not welcome, he says.

Thailand is known for its tough anti-drug laws. As it stands, the Public Health act levies a punishment of up to three months in jail and a fine of $800 for lighting up in public. According to Anutin, the government has never considered legalizing cannabis for recreational consumption or to be used in ways that could “irritate others.”

The Public Health Ministry also announced that more than 3,000 inmates who were imprisoned for hemp- and cannabis-related drug offenses will soon be released. In wake of the legalization news, marijuana advocacy group Highland Legalization has organized a weekend festival that will involve panel discussions, musical performances and cannabis food sales.

However, some activists are still apprehensive about Thailand’s new cannabis policies as law enforcement hasn’t been as quick to adapt to changing laws. Thailand first decriminalized medical cannabis use in 2018 and has been steadily loosening its cannabis laws under Anutin’s watchful eye.

However, law enforcement hasn’t always kept up with these changes. A few weeks ago, a 56-year-old woman in eastern Chonburi Province who had diabetes and high blood pressure was arrested by plainclothes police officers after they saw a potted cannabis plant in her bedroom. Anutin states that the four officers have already been disciplined. He adds that the government will need to educate both law enforcers and ordinary citizens about the evolving cannabis laws.

As the strict marijuana laws around the region begin to loosen, an opportunity may be created for established cannabis companies such as Flora Growth Corp. (NASDAQ: FLGC) to expand into these emerging markets.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

  • Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension
  • The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing
  • The pre-IND meeting will confirm the details of the company’s IND-enabling program
  • Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science

Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension (https://cnw.fm/rDcfI).

According to the September 8 news release, Lexaria had retained the services of an expert regulatory affairs and quality assurance consulting group that would help prepare the company for a pre-IND meeting with the FDA. The group would also assist Lexaria with designing the requisite non-clinical, clinical, and related product development IND-enabling work/program meant to be finalized before the company files its IND application.

Through the intervening period, Lexaria has made progress bringing it closer to achieving these goals, recently reporting it had filed a pre-IND meeting request letter with the FDA. The request, to which the federal agency had already responded and set a target date of July 30, 2022 (subject to the fulfillment of certain conditions), formally initiated communication with the FDA concerning the development of DehydraTECH-CBD as a treatment for hypertension (https://cnw.fm/SNVqc).

“We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” commented Lexaria President John Docherty. “Submission of this request letter initiates formal communication with the FDA regarding our IND clinical trial plans in order to help define the critical path for clinical development and marketing approval of our potentially very significant new hypertension therapeutic.”

The pre-IND meeting is intended to confirm the details and acceptability of Lexaria’s IND-enabling work, which is set to be completed after the meeting has been held. This work has been made possible by the company’s growing body of evidence showing DehydraTECH-CBD’s capacity to potentially treat hypertension. 

Through its successfully completed studies – HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3 – Lexaria has not only demonstrated that DehydraTECH-CBD lowers the human blood pressure relative to placebo and reduces arterial stiffness but also that it does not cause any adverse effects. According to the company’s recent statement, efficacy and the lack of negative side effects are the two main goals of FDA-registered clinical studies.

Following the pre-IND meeting and the completion of the IND-enabling development program, Lexaria expects to then proceed with its full IND application filing expected in late 2022 or early 2023. 

Meanwhile, the company also celebrated another milestone that saw it expand the list of licensees. In a recent announcement, Lexaria reported that its wholly owned subsidiary, Lexaria Pharmaceutical Corp., had awarded a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals of Ireland (https://cnw.fm/ZrHuV).

The license allows AnodGen, a newly established contract manufacturing organization business, to manufacture and distribute DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe (including the UK), Australia, and New Zealand. The license also covers pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen can also manufacture and sell the API powders to third-party companies for their own products, subject to the fulfillment of specific conditions. On its part, Lexaria will receive royalty fees for all API powders sold that utilize the DehydraTECH drug delivery technology.

This licensing agreement comes on the heels of two similar agreements that saw Lexaria Pharmaceutical Corp. grant a European and UK license to medical cannabis manufacturer Valcon Medical A/S (https://cnw.fm/eHkdp) and a license to Premier Wellness Science Co. Ltd to deploy DehydraTECH within the Japanese non-pharmaceutical market (https://cnw.fm/cfkkH). 

“We are focused on larger national and international applications for DehydraTECH, primarily but not entirely in the pharmaceutical sector. These are our areas of interest that we expect will provide significant revenue streams over time…,” commented Lexaria CEO Chris Bunka in a January letter to shareholders (https://cnw.fm/pcj9E). With the series of out-licenses announced recently, Lexaria appears to be inching closer to realizing this goal.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Senator Asks Congress to Allow Cannabis Businesses to Access Business Loans

America’s cannabis industry exists in a sort of limbo. Although dozens of states now allow the cultivation and sale of cannabis to adults aged 21 and older, federal law still outlaws the plant and considers it a Schedule I controlled drug.

This means that even though licensed cannabis businesses are seen as legal commercial enterprises by many states, they cannot access many of the services other industries enjoy. One such service is benefits and grants from the federal government. Cannabis businesses felt this most acutely during the coronavirus pandemic when the national government deployed aid funds to businesses through the federal Small Business Administration (SBA) loans program, but federal law prevented the cannabis companies from accessing much-needed funds.

Senator Jacky Rosen is now requesting that marijuana businesses be granted access to SBA loans as well as other federal resources via an impending spending bill. A persistent supporter of the cannabis industry’s right to access SBA resources without any restrictions, the senator sent a letter to the Senate Appropriations Committee. She requested that language preventing the SBA from denying small cannabis businesses federal loans be added to the Financial Services and General Government Related Agencies Appropriations Bill for fiscal year 2023.

This language would allow state-legal cannabis businesses to access loans from the Disaster Assistance Program, Microloan Program, Loan Guarantee Program and the 504/Certified Development Company Loan Program. The letter also requests that state-legal cannabis businesses be allowed to participate in the Small Business Administration’s entrepreneurial development programs.

The Nevada senator noted that states are now seeing billions of dollars’ worth of cannabis sales and the numbers are expected to rise as even more states move to legalize either recreational or medical cannabis in 2022.

But despite the fact that the cannabis businesses pay billions of dollars in taxes, SBA policy currently excludes businesses that directly or indirectly deal with cannabis from its entrepreneurial development and loan programs. This locks out cannabis businesses as well as enterprises outside the industry that choose to take advantage of the extremely profitable cannabis industry.

Rosen also raised the issue last year during a Senate Small Business and Entrepreneurship Committee hearing during which SBA administrator Isabel Guzman said she would look into granting cannabis businesses access to SBA loans.

Last July, Rosen and nine other senators penned a letter to the leadership of the Senate Appropriations Committee requesting that marijuana businesses be allowed to access federal Small Business Administration loans.

If access to this funding is granted, the sector would grow more steadily and more companies as well as individuals may be interested in giving advanced cultivation equipment such as the grow containers made by Advanced Container Technologies Inc. (OTC: ACTX) and similar companies a try.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Concludes Cannabis Is Safe, Effective in Treating Cancer Pain

Israeli researchers recently published a scientific paper proving that cannabis has the potential to provide chronic pain relief to patients undergoing cancer treatment. Such patients are typically prescribed pharmaceutical painkillers to manage their pain during treatment. But while these drugs can be effective at reducing pain, they tend to cause adverse side effects such as addiction.

Researchers have been on the lookout for a drug that can provide the same pain relief without any of the side effects for quite a while. The paper notes that while medical cannabis can also have side effects, those effects can be categorized as “mild to moderate” and are generally well tolerated.

The study authors state that there were relatively few small-scale studies on marijuana’s pain-relief abilities before they ran their study, which involved 404 cancer patients. The patients were prescribed an initial dose of 20 grams of medical cannabis a month that could either be smoked or taken as an oil extract. They were asked to answer questions about their cancer treatment symptoms before treatment began and at certain points during the entire six-month study.

The paper, which was published in the journal “Frontiers in Pain Research,” states that total cancer symptoms were reduced by an 18% average rating while average weekly pain intensity dropped by a 20% median. Furthermore, the patients didn’t need to increase their dosages during the six months for the cannabis to be effective. In total, 40% of the patients stopped using pharmaceutical analgesics after the study concluded.

However, 20% picked up their analgesic use after the study while 25% of the patients reported that their pain increased in intensity after they stopped the cannabis treatment. The researchers posit that the patients who didn’t need to go back to pharmaceutical pain killers after the study had “less severe disease” and thus had fewer comorbidities by the time the study wrapped up.

Their conclusion was that cannabis has the potential to provide “mild to modest long-term improvement” in cancer-associated symptoms, including pain. Most importantly, the paper states, it can lead to a reduction in the use of opioids and other analgesics that aren’t always risk free. However, the study authors note that survival bias may have affected their results and that medical cannabis may have “limited efficacy and clinical relevance.”

Technion Israel Institute of Technology and study coauthor David Meiri says we will need future studies to investigate how effective medical cannabis can be when used by patients with specific types of cancer and specific shared characteristics.

As the therapeutic potential of cannabis is affirmed by more scientific studies, the products made by companies such as American Cannabis Partners are likely to gain broader public trust, and consumption habits could ultimately be shaped by the information about the medicinal benefits of these substances.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system components; the results indicate that each cannabinoid had distinct biological activity via the endocannabinoid system. The study was conducted in collaboration with Dr. Mauro Maccarrone, professor and chair of biochemistry at the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said InMed Pharmaceuticals senior VP of preclinical research and development Dr. Eric Hsu in the press release. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”

To view the report, visit https://cnw.fm/yJy9P

To view the full press release, visit https://cnw.fm/U1F9I

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and is dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.